Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

A preliminary serotherapeutic trial was undertaken with a monoclonal antibody designated antibody 89 (Ab 89) directed against a lymphoma-associated antigen. In vitro studies demonstrated that Ab 89 could mediate complement-dependent lysis and macrophage adherence but not antibody-dependent cell-medi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1980-09, Vol.40 (9), p.3147
Main Authors: Nadler, L M, Stashenko, P, Hardy, R, Kaplan, W D, Button, L N, Kufe, D W, Antman, K H, Schlossman, S F
Format: Article
Language:English
Subjects:
Antibodies, Neoplasm - administration & dosage
Antibody-Dependent Cell Cytotoxicity
Antigens, Neoplasm - immunology
Cell Adhesion
Drug Administration Schedule
Evaluation Studies as Topic
Humans
Immunization, Passive
Leukocyte Count
Lymphoma - immunology
Lymphoma - therapy
Macrophages - immunology
Male
Middle Aged
Neoplastic Cells, Circulating
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A preliminary serotherapeutic trial was undertaken with a monoclonal antibody designated antibody 89 (Ab 89) directed against a lymphoma-associated antigen. In vitro studies demonstrated that Ab 89 could mediate complement-dependent lysis and macrophage adherence but not antibody-dependent cell-mediated cytotoxicity. To evaluate toxicity and therapeutic efficacy, two courses of Ab 89 were administered to a patient with an Ab 89-reactive tumor. Transient decreases in the number of circulating tumor cells and the appearance of circulating dead cells were noted with the infusion of Ab 89. Following administration of 150 mg or more of Ab 89, small amounts of antibody could be demonstrated on circulating tumor cells at a time when no free antibody was found in the serum. The inability to deliver a significant amount of Ab 89 to tumor cells in vivo is thought to be secondary to a circulating tumor antigen. Following each infusion, the amount of this blocking antigen decreased but could not be entirely cleared from the serum. This study provides preliminary evidence for the lack of clinical toxicity of a monoclonal antibody and identifies circulating blocking antigens as a significant obstacle to serotherapy.
ISSN:0008-5472